Literature DB >> 16226182

Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients.

Elena Biagini1, Fabio Coccolo, Marinella Ferlito, Enrica Perugini, Guido Rocchi, Letizia Bacchi-Reggiani, Carla Lofiego, Giuseppe Boriani, Daniela Prandstraller, Fernando M Picchio, Angelo Branzi, Claudio Rapezzi.   

Abstract

OBJECTIVES: This study sought to investigate the incidence, risk factors, and prognosis of dilated-hypokinetic evolution in a large cohort of patients with hypertrophic cardiomyopathy (HCM) followed up at a cardiology center serving both the pediatric and the adult population.
BACKGROUND: The available data on this evolution of HCM mainly regards prevalence (rather than incidence) in adults, with very little being known about the pediatric population.
METHODS: A total of 222 consecutive HCM patients (65% men, 19% < or =18 years old) were prospectively evaluated for a mean follow-up of 11 +/- 9 years.
RESULTS: A diagnosis of dilated-hypokinetic HCM was made in 12 patients at first evaluation (11 without previous septal myectomy surgery; prevalence, 4.9%). Twelve of the 210 patients with classic HCM at first evaluation underwent dilated-hypokinetic evolution (incidence, 5.3/1,000 patient-years). Patients with prevalent/incident dilated-hypokinetic evolution were younger at first evaluation (32 +/- 14 years vs. 41 +/- 21 years, p = 0.04) and more often had a family history of HCM (61% vs. 26%, p = 0.002) or sudden death (43% vs. 19%, p = 0.01) with respect to patients who maintained classic HCM. Moreover, they showed greater interventricular septum (23 +/- 3 mm vs. 19 +/- 6 mm, p = 0.004) and posterior wall (15 +/- 3 mm vs. 13 +/- 4 mm, p = 0.006) thickness. Cardiovascular death-free survival was lower among patients with dilated-hypokinetic HCM (p < 0.04). Cox proportional hazards regression analysis identified left ventricular wall thickness (hazard ratio [HR] = 1.07; 95% confidence interval [CI], 1.01 to 1.14; p = 0.03) and end-diastolic diameter (HR = 1.08; 95% CI 1.04 to 1.11; p = 0.0001) as independent predictors of cardiovascular death.
CONCLUSIONS: Dilated-hypokinetic evolution is rare but not exceptional in HCM. Young age at diagnosis, family history of HCM, and greater wall thickness are incremental risk factors for dilated-hypokinetic HCM, which carries an ominous prognosis.

Entities:  

Mesh:

Year:  2005        PMID: 16226182     DOI: 10.1016/j.jacc.2005.04.062

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  42 in total

Review 1.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

Review 2.  Hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho
Journal:  Heart Fail Clin       Date:  2010-04       Impact factor: 3.179

3.  MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart disease.

Authors:  Minako Takeda; Yasuo Amano; Masaki Tachi; Hitomi Tani; Kyoichi Mizuno; Shinichiro Kumita
Journal:  Jpn J Radiol       Date:  2013-08-31       Impact factor: 2.374

Review 4.  Management of hypertrophic cardiomyopathy.

Authors:  Paolo Spirito; Camillo Autore
Journal:  BMJ       Date:  2006-05-27

Review 5.  The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy.

Authors:  Lucie Carrier; Saskia Schlossarek; Monte S Willis; Thomas Eschenhagen
Journal:  Cardiovasc Res       Date:  2009-07-17       Impact factor: 10.787

6.  Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction.

Authors:  Akira Funada; Hideaki Kanzaki; Teruo Noguchi; Yoshiaki Morita; Yasuo Sugano; Takahiro Ohara; Takuya Hasegawa; Hiromi Hashimura; Hatsue Ishibashi-Ueda; Masafumi Kitakaze; Satoshi Yasuda; Hisao Ogawa; Toshihisa Anzai
Journal:  Heart Vessels       Date:  2015-03-28       Impact factor: 2.037

7.  Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies.

Authors:  J Malcom; O Arnold; Jonathan G Howlett; Anique Ducharme; Justin A Ezekowitz; Martin J Gardner; Nadia Giannetti; Haissam Haddad; George A Heckman; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Errol J Sequeira; Michel White
Journal:  Can J Cardiol       Date:  2008-01       Impact factor: 5.223

8.  Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations.

Authors:  Cordula M Wolf; Michael Arad; Ferhaan Ahmad; Atsushi Sanbe; Scott A Bernstein; Okan Toka; Tetsuo Konno; Gregory Morley; Jeffrey Robbins; J G Seidman; Christine E Seidman; Charles I Berul
Journal:  Circulation       Date:  2007-12-24       Impact factor: 29.690

Review 9.  Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment.

Authors:  Maria-Angela Losi; Stefano Nistri; Maurizio Galderisi; Sandro Betocchi; Franco Cecchi; Iacopo Olivotto; Eustachio Agricola; Piercarlo Ballo; Simona Buralli; Antonello D'Andrea; Arcangelo D'Errico; Donato Mele; Susanna Sciomer; Sergio Mondillo
Journal:  Cardiovasc Ultrasound       Date:  2010-03-17       Impact factor: 2.062

10.  Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy.

Authors:  Paola Melacini; Cristina Basso; Annalisa Angelini; Chiara Calore; Fabiana Bobbo; Barbara Tokajuk; Nicoletta Bellini; Gessica Smaniotto; Mauro Zucchetto; Sabino Iliceto; Gaetano Thiene; Barry J Maron
Journal:  Eur Heart J       Date:  2010-05-31       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.